[Malignant mixed müllerian tumor of the uterus following tamoxifen for breast cancer: case report]

M Saim; J-F Cote; O Morel; C Malartic; G Akerman; F Gray; E Barranger

doi:10.1016/j.gyobfe.2007.06.020

[Malignant mixed müllerian tumor of the uterus following tamoxifen for breast cancer: case report]

Gynecol Obstet Fertil. 2008 Feb;36(2):166-168. doi: 10.1016/j.gyobfe.2007.06.020. Epub 2008 Feb 4.

[Article in French]

Authors

M Saim¹, J-F Cote², O Morel¹, C Malartic¹, G Akerman¹, F Gray², E Barranger³

Affiliations

¹ Service de gynécologie-obstétrique, hôpital Lariboisière, Assistance publique des Hôpitaux de Paris (AP-HP), 2, rue Ambroise-Paré, 75010 Paris, France.
² Service d'anatomie pathologique, hôpital Lariboisière, Assistance publique des Hôpitaux de Paris (AP-HP), 2, rue Ambroise-Paré, 75010 Paris, France.
³ Service de gynécologie-obstétrique, hôpital Lariboisière, Assistance publique des Hôpitaux de Paris (AP-HP), 2, rue Ambroise-Paré, 75010 Paris, France. Electronic address: ebarrang@club-internet.fr.

PMID: 18249575
DOI: 10.1016/j.gyobfe.2007.06.020

Abstract

Tamoxifen is an antioestrogen widely used in the breast cancer treatment. Its paradoxical antioestrogenic action on breast and its oestrogenic action on the endometer is well-known. Since 1988, few cases of malignant mixed müllerian tumors following tamoxifen were described. We report a new case of uterine malignant mixed müllerian tumor four years after the end of tamoxifen for breast cancer.

Publication types

Case Reports
English Abstract

MeSH terms

Aged, 80 and over
Antineoplastic Agents, Hormonal / adverse effects*
Antineoplastic Agents, Hormonal / therapeutic use
Breast Neoplasms / drug therapy*
Female
Humans
Mixed Tumor, Mullerian / chemically induced*
Mixed Tumor, Mullerian / pathology
Tamoxifen / adverse effects*
Tamoxifen / therapeutic use
Uterine Neoplasms / chemically induced*
Uterine Neoplasms / pathology

Substances

Antineoplastic Agents, Hormonal
Tamoxifen